Neurophth
Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | CNY700m Valuation: CNY3.5b | Series C | |
| Total Funding | 000k | ||
Related Content
Neurophth is a clinical-stage gene therapy company focused on the development of treatments for ophthalmic diseases. The company was founded in 2016 by Professor Bin Li, a leading expert in ophthalmology and gene therapy.
Professor Li's research has been focused on the development of novel gene therapies for inherited retinal diseases. His work has led to the development of Neurophth's lead product candidate, NR082, which is currently in clinical trials for the treatment of Leber's hereditary optic neuropathy (LHON), a rare genetic disorder that causes vision loss.
Neurophth's business model is based on the development and commercialization of its gene therapy products. The company plans to partner with pharmaceutical companies to bring its products to market. Neurophth's target market is the global ophthalmic market, which is estimated to be worth over $50 billion.
The company has raised over $100 million in funding from a variety of investors, including venture capital firms and strategic partners. Neurophth is headquartered in Wuhan, China, and has offices in the United States and Europe.
Keywords: gene therapy, ophthalmology, retinal diseases, Leber's hereditary optic neuropathy, clinical trials, AAV, CMC, NR082, vision loss, genetic disorders